TMQA Latest News

EMA Update on Publication of Clinical Trial Data

On 24 June 2015, the EMA held a webinar to provide an update on the implementation of its policy on the publication of clinical data which came into effect on 01 January 2015. The topics covered in the webinar included an explanation of the principles for the submission of redacted clinical reports, the redaction consultation progress as well as guidance on what is and is not considered commercially confidential information and on the anonymisation and redaction of personal data in clinical reports. The video recording of the webinar as well as slides of all the presentations given have now been published on the EMA website and can be found on:

http://tinyurl.com/pfxo6bg


TMQA strengthens partnership with BioCity Scotland

We are delighted to announce that TMQA has strengthened its relationship with BioCity Scotland by upgrading from Service Associates to Corporate Partners.  As Service Associates the TMQA team provided an onsite “drop in” QA advice service for tenants two days a month.   Over the last two years, we have supported several tenants by providing advice on regulatory requirements and compliance, supporting the implementation of quality management systems and conducting independent GMP (Good Manufacturing Practice) audits.

TMQA Director, Andrew Waddell, commented: “Developing a closer relationship with Biocity and its tenants gives them access to a range of Quality Assurance services which can change and develop along with their companies.  Using our ‘pay-as-you-go’ service means that they don’t need to invest in the overhead costs of hiring their own QA staff – they can use TMQA services whenever they need and only pay for the actual time involved.   Active partnering with organisations – small or large – is at the core of our business plan and our relationship with Biocity is an exciting development for us.”


Clinical Quality Assurance – Career Development Opportunities

TMQA is looking to expand its team of Clinical Quality Assurance (CQA) professionals.

Your Background

Applicants should have a minimum of 3 years’ relevant experience.  This experience will ideally be in CQA, however, we are also keen to offer career development opportunities to applicants in other areas of clinical research (eg. CRAs) who would like to move into CQA.

The Job

The major part of the job will be undertaking audits of clinical trials, usually at investigator sites.  The job will involve travel in the UK and Europe with the possibility of travel further afield.  Typically you will conduct two audits per month each of which will involve 2-3 days on site.

Relevant experience in clinical trials is essential as well as an ability to work independently (after initial training).  You will have the personal skills to interact professionally with clinical research staff at all levels.  A key element will be to analyse the evidence gathered during the audit and present findings clearly and concisely both verbally and in a written report.

Location

We have offices in Edinburgh and Bratislava.  Staff who are transitioning into QA would need to be based in one of these offices.  Home-based positions will be considered for staff who are already experienced CQA Auditors.

Interested?

For further information please contact careers@tmqa.co.uk


New MHRA Inspectorate Blog

The MHRA Inspectorate blog is aimed at those organisations that are inspected by MHRA and need to keep up to date with the latest thinking and guidelines.  

Find out more at:  https://mhrainspectorate.blog.gov.uk/


EMA Tightens Rules on ‘Revolving Door’ for Committee Members and Experts

The EMA has tightened its rules on declarations of interest by committee members and experts by restricting the involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry. The EMA’s updates also include a revised guide on how to complete the EMA’s declaration of interest form. The EMA’s declaration of interest policy aims to restrict the involvement of experts with possible conflicts of interest in the EMA’s work while maintaining EMA’s ability to access the best available expertise. The EMA considers that employment in a pharmaceutical company is incompatible with an involvement in the EMA’s activities. Whenever a member of a scientific committee or working party informs the EMA that he/she intends to work for a pharmaceutical company, the EMA will immediately restrict the member from any participation from evaluation of medicines. In March 2014, the EMA management board endorsed a major revision of EMA’s policy on handling declarations of interest for scientific committee members and experts. The revision took into account input form stakeholders at the EMA’s September 2013 public workshop “Best expertise v conflicts of interests: striking the right balance”. It entered into force in January 2015. The EMA will continue to review its policy on a regular basis.  

http://tinyurl.com/q44s3ch